Bio＆Healthcare
Business Division
WAFTEC BIO

References

Usui M, Saito A, Taniguchi N, Nishijima N, Azakami H, Kato A. Reduction of antigenicity of Cry j I, major allergen of Japanese cedar pollen, by the attachment of polysaccharides. Biosci Biotechnol Biochem. 2003;67(11):2425-2430.

Aoki R, Saito A, Usui M, Azakami H, Kato A. Reduction of antigenicity of Cry j 1, a major allergen of Japanese cedar pollen, by thermal denaturation. J Agric Food Chem. 2009;57(11):4995-9.

Aoki R, Saito A, Azakami H, Kato A. Effects of various saccharides on the masking of epitope sites and uptake in the gut of cedar allergen Cry j 1-saccharide conjugates by a naturally occurring Maillard reaction. J Agric Food Chem. 2010;58(13):7986-7990.

Murakami D, Kubo K, Sawatsubashi M, Kikkawa S, Ejima M, Saito A, Kato A, Komune S. Phase I/II study of oral immunotherapy with Cry j1-galactomannan conjugate for Japanese cedar pollinosis. Auris Nasus Larynx. 2014;41(4):350-8.

Murakami D, Sawatsubashi M, Kikkawa S, Ejima M, Saito A, Kato A, Komune S. Safety and efficacy of a new regimen of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a prospective, randomized, open-label study. Allergol Int. 2015;64(2):161-8.

Murakami D, Sawatsubashi M, Kikkawa S, Ejima M, Saito A, Kato A, Komune S. Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study. Auris Nasus Larynx. 2016;43(1):50-5.

Murakami D, Sawatsubashi M, Omori H, Saito A, Kato A, Komune S, Nakagawa T. Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a randomized controlled trial. Sci Rep. 2017;7:46142.